Cover Image

Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children

IntroductionNon-invasive pneumococcal pneumonia (NIPP) is possibly the most frequent infection by Streptococcus pneumoniae in adults. However, the herd effect of vaccinating children in adult NIPP (aNIPP) remains poorly characterized.MethodsWe determined the serotype distribution and antimicrobial s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Catarina Silva-Costa (Author), Joana Gomes-Silva (Author), Andreia Santos (Author), Mário Ramirez (Author), José Melo-Cristino (Author), The Portuguese Group for the Study of Streptococcal Infections (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Maria L. Avila-Aguero, et al.
Published: (2017)

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Javier Nieto Guevara, et al.
Published: (2018)

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019
by: Eiman Mokaddas, et al.
Published: (2021)

Vaccination status (PCV13) of children with pneumococcal meningitis
by: Seidullayeva, Aliya, et al.
Published: (2020)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Mastoiditis with Streptococcus pneumoniae serotype 19A in one-dose PCV13 vaccinated three-month-old infant
by: B. Gülhan, et al.
Published: (2019)

A systematic review about Streptococcus Pneumoniae serotype distribution in children in mainland of China before the PCV13 was licensed
by: Shuang Lyu, et al.
Published: (2017)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019)

Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
by: Josiah Ryman, et al.
Published: (2024)

Changes in invasive pneumococcal disease serotypes in a regional area of Australia following three years of 7vPCV introduction
by: Fakhrul Islam, et al.
Published: (2012)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
by: Jorge A. Gómez, et al.
Published: (2022)

Impact of PCV13 vaccination in Blantyre, Malawi
by: Portia Kamthunzi
Published: (2021)

Co-occurrence of bacteria and viruses and serotype distribution of Streptococcus pneumoniae in the nasopharynx of Tanzanian children below 2 years of age following introduction of the PCV13
by: Matilda Emgård, et al.
Published: (2024)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024)

Serotype distribution, antibiotic resistance pattern, and multilocus sequence types of invasive Streptococcus pneumoniae isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability
by: Wei Shi, et al.
Published: (2019)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022)

Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine
by: Timothy J. Chapman, et al.
Published: (2020)

Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
by: Josiah Ryman, et al.
Published: (2024)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
by: Paolo Castiglia, et al.
Published: (2017)

Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial
by: Courtney P. Olwagen, et al.
Published: (2024)

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10
by: Germán Camacho Moreno, et al.
Published: (2020)

Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls
by: S. Shahzad Mustafa, et al.
Published: (2019)

Estimates on state-specific Pneumococcal Conjugate Vaccines (PCV) coverage in the private sector in the year 2012: Evidence from PCV utilization data
by: Habib Hasan Farooqui, et al.
Published: (2016)

Reply to 'Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10'
by: Javier Nieto Guevara, et al.
Published: (2020)

The economic impact of the switch from single- to multi-dose PCV13 vial in Benin
by: Patrick G. Ilboudo, et al.
Published: (2022)

Introduction of multi-dose PCV 13 vaccine in Benin: from the decision to vaccinators experience
by: Daleb Abdoulaye Alfa, et al.
Published: (2020)

Changes in the incidence of acute bacterial meningitis caused by Streptococcus pneumoniae and the implications of serotype replacement in children in Colombia after mass vaccination with PCV10
by: Juan David Farfán-Albarracín, et al.
Published: (2022)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024)

Is Pneumococcal Serotype Replacement Impending?
by: Chun-Yi Lu, et al.
Published: (2016)

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018
by: Larisa Savrasova, et al.
Published: (2021)

Decision-making for PCV in adults
by: John M. McLaughlin, et al.
Published: (2019)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
by: Derek Lytle, et al.
Published: (2023)

Impact of PCV10 on pediatric pneumococcal disease burden in Brazil: time for new recommendations?
by: Daniel Jarovsky, et al.
Published: (2023)

Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China
by: Ran Hu, et al.
Published: (2023)

Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries
by: Preetika Banerjee, et al.
Published: (2023)

Development of an indirect immunofluorescence assay for PCV3 antibody detection based on capsid protein
by: Lun Yao, et al.
Published: (2021)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
by: Youness Lagoubi, et al.
Published: (2022)

Invasive pneumococcal disease in relation to vaccine type serotypes
by: Paeton L. Wantuch, et al.
Published: (2019)

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines
by: Qian-qian Du, et al.
Published: (2021)

Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies
by: Naor Bar-Zeev, PhD, et al.
Published: (2021)